Related Experiment Video
Updated: May 25, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Treating impaired cognition in schizophrenia.
1Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX 75390-9086, USA. Hicham.Ibrahim@utsouthwestern.edu
Current Pharmaceutical Biotechnology
|January 31, 2012
Summary
Schizophrenia treatment shows minimal impact on cognitive dysfunction. Novel pharmacologic and psychological strategies targeting acetylcholine, dopamine, and glutamate receptors are needed to improve cognition in patients.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cognitive impairment is a primary feature of schizophrenia, significantly impacting daily functioning and social relationships.
- Current antipsychotic medications effectively manage positive symptoms but offer limited benefits for cognitive deficits.
- There is a growing need for innovative treatments to address cognitive dysfunction in schizophrenia.
Purpose of the Study:
- To review promising pharmacologic strategies for improving cognition in schizophrenia.
- To identify key molecular targets for novel cognitive treatments.
- To explore the potential of combined pharmacological and psychological interventions.
Main Methods:
- Literature review of pharmacologic strategies targeting neurotransmitter systems.
- Analysis of molecular targets implicated in cognitive function.
- Discussion of evidence for novel treatment approaches.
Main Results:
- Several molecular targets show potential for enhancing cognition, including receptors for acetylcholine, dopamine, glutamate, GABA, serotonin, and histamine.
- Current drug development has primarily focused on positive symptoms, with limited success in treating cognitive deficits.
- Pharmacological interventions targeting specific neurotransmitter systems are under investigation.
Conclusions:
- Novel pharmacological treatments targeting specific molecular pathways are crucial for addressing cognitive impairment in schizophrenia.
- A combination of pharmacological and psychological interventions may offer the most effective approach to enhancing cognition.
- Further research into these targets is essential for developing effective therapies for schizophrenia-related cognitive dysfunction.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...